Logo image of AFMD

AFFIMED NV (AFMD) Stock Fundamental Analysis

NASDAQ:AFMD - Nasdaq - NL0015001ZQ0 - Common Stock - Currency: USD

0.992  +0 (+0.2%)

Fundamental Rating

2

Overall AFMD gets a fundamental rating of 2 out of 10. We evaluated AFMD against 572 industry peers in the Biotechnology industry. AFMD has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, AFMD is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AFMD had negative earnings in the past year.
AFMD had a negative operating cash flow in the past year.
AFMD had negative earnings in each of the past 5 years.
In the past 5 years AFMD always reported negative operating cash flow.
AFMD Yearly Net Income VS EBIT VS OCF VS FCFAFMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -175.10%, AFMD is doing worse than 86.56% of the companies in the same industry.
AFMD's Return On Equity of -406.92% is on the low side compared to the rest of the industry. AFMD is outperformed by 76.96% of its industry peers.
Industry RankSector Rank
ROA -175.1%
ROE -406.92%
ROIC N/A
ROA(3y)-59.16%
ROA(5y)-45.97%
ROE(3y)-93.94%
ROE(5y)-84.6%
ROIC(3y)N/A
ROIC(5y)N/A
AFMD Yearly ROA, ROE, ROICAFMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

Looking at the Gross Margin, with a value of 789.74%, AFMD belongs to the top of the industry, outperforming 99.83% of the companies in the same industry.
In the last couple of years the Gross Margin of AFMD has declined.
AFMD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 789.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.76%
GM growth 5Y-2.54%
AFMD Yearly Profit, Operating, Gross MarginsAFMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

More info and screens

2

2. Health

2.1 Basic Checks

AFMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AFMD remains at a similar level compared to 1 year ago.
The number of shares outstanding for AFMD has been increased compared to 5 years ago.
AFMD has a worse debt/assets ratio than last year.
AFMD Yearly Shares OutstandingAFMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M
AFMD Yearly Total Debt VS Total AssetsAFMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

AFMD has an Altman-Z score of -4.05. This is a bad value and indicates that AFMD is not financially healthy and even has some risk of bankruptcy.
AFMD has a Altman-Z score (-4.05) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.35 indicates that AFMD is not too dependend on debt financing.
AFMD's Debt to Equity ratio of 0.35 is on the low side compared to the rest of the industry. AFMD is outperformed by 71.90% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF N/A
Altman-Z -4.05
ROIC/WACCN/A
WACC8.41%
AFMD Yearly LT Debt VS Equity VS FCFAFMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M -100M 150M

2.3 Liquidity

AFMD has a Current Ratio of 1.93. This is a normal value and indicates that AFMD is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.93, AFMD is doing worse than 75.74% of the companies in the same industry.
AFMD has a Quick Ratio of 1.93. This is a normal value and indicates that AFMD is financially healthy and should not expect problems in meeting its short term obligations.
AFMD has a worse Quick ratio (1.93) than 74.17% of its industry peers.
Industry RankSector Rank
Current Ratio 1.93
Quick Ratio 1.93
AFMD Yearly Current Assets VS Current LiabilitesAFMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

AFMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.15%, which is quite impressive.
AFMD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -95.39%.
The Revenue for AFMD have been decreasing by -19.00% on average. This is quite bad
EPS 1Y (TTM)42.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.25%
Revenue 1Y (TTM)-95.39%
Revenue growth 3Y-33.67%
Revenue growth 5Y-19%
Sales Q2Q%-92.1%

3.2 Future

Based on estimates for the next years, AFMD will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.86% on average per year.
The Revenue is expected to grow by 37.71% on average over the next years. This is a very strong growth
EPS Next Y40.97%
EPS Next 2Y29.01%
EPS Next 3Y19.02%
EPS Next 5Y10.86%
Revenue Next Year-81.84%
Revenue Next 2Y-23.09%
Revenue Next 3Y14.98%
Revenue Next 5Y37.71%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AFMD Yearly Revenue VS EstimatesAFMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
AFMD Yearly EPS VS EstimatesAFMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -50 -100 -150 -200

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AFMD. In the last year negative earnings were reported.
Also next year AFMD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AFMD Price Earnings VS Forward Price EarningsAFMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AFMD Per share dataAFMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4

4.3 Compensation for Growth

AFMD's earnings are expected to grow with 19.02% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.01%
EPS Next 3Y19.02%

More info and screens

0

5. Dividend

5.1 Amount

AFMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AFFIMED NV

NASDAQ:AFMD (3/7/2025, 8:03:52 PM)

0.992

+0 (+0.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)03-27 2025-03-27/amc
Inst Owners22.64%
Inst Owner Change-85.5%
Ins Owners6.01%
Ins Owner ChangeN/A
Market Cap15.11M
Analysts83.64
Price Target13.87 (1298.19%)
Short Float %4.91%
Short Ratio2.83
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.56%
Min EPS beat(2)-10.88%
Max EPS beat(2)1.75%
EPS beat(4)3
Avg EPS beat(4)4.52%
Min EPS beat(4)-10.88%
Max EPS beat(4)14.22%
EPS beat(8)4
Avg EPS beat(8)1.65%
EPS beat(12)7
Avg EPS beat(12)6.57%
EPS beat(16)8
Avg EPS beat(16)-11.38%
Revenue beat(2)0
Avg Revenue beat(2)-90.72%
Min Revenue beat(2)-92.4%
Max Revenue beat(2)-89.04%
Revenue beat(4)0
Avg Revenue beat(4)-85.87%
Min Revenue beat(4)-92.4%
Max Revenue beat(4)-74.24%
Revenue beat(8)2
Avg Revenue beat(8)-47.19%
Revenue beat(12)4
Avg Revenue beat(12)-23.39%
Revenue beat(16)7
Avg Revenue beat(16)-15.7%
PT rev (1m)-12.26%
PT rev (3m)-41.95%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-25.75%
EPS NY rev (1m)-2%
EPS NY rev (3m)-12.34%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.56%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-63.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 15.87
P/FCF N/A
P/OCF N/A
P/B 0.81
P/tB 0.81
EV/EBITDA N/A
EPS(TTM)-4.96
EYN/A
EPS(NY)-2.57
Fwd EYN/A
FCF(TTM)-5.52
FCFYN/A
OCF(TTM)-5.48
OCFYN/A
SpS0.06
BVpS1.23
TBVpS1.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -175.1%
ROE -406.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 789.74%
FCFM N/A
ROA(3y)-59.16%
ROA(5y)-45.97%
ROE(3y)-93.94%
ROE(5y)-84.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.76%
GM growth 5Y-2.54%
F-Score1
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.61%
Cap/Sales 60.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.93
Quick Ratio 1.93
Altman-Z -4.05
F-Score1
WACC8.41%
ROIC/WACCN/A
Cap/Depr(3y)175.27%
Cap/Depr(5y)145.6%
Cap/Sales(3y)18.76%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.25%
EPS Next Y40.97%
EPS Next 2Y29.01%
EPS Next 3Y19.02%
EPS Next 5Y10.86%
Revenue 1Y (TTM)-95.39%
Revenue growth 3Y-33.67%
Revenue growth 5Y-19%
Sales Q2Q%-92.1%
Revenue Next Year-81.84%
Revenue Next 2Y-23.09%
Revenue Next 3Y14.98%
Revenue Next 5Y37.71%
EBIT growth 1Y42.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-8.45%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y25.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.28%
OCF growth 3YN/A
OCF growth 5YN/A